Pharmgate acquires chlortetracycline product licenses in Latin America.

August 08, 2013 — Pharmgate LLC of Ramsey, New Jersey is pleased to announce the acquisition of a number of chlortetracycline product registrations in Latin America. As the majority owned US subsidiary of Jinhe Biotechnology, the largest manufacturer of chlortetracycline in the world, Pharmgate will become a significant supplier of its branded chlortetracycline products in the Latin American market.

At the same time, Pharmgate is pleased to announce the appointment of Alfonso Rueda as Business Manager, Latin America to manage its growing business in these markets. Mr. Rueda, based in Colombia, has a strong background in the Latin American animal nutrition and health industry with companies such as American Cyanamid, Roche, DSM and Provimi.

Pharmgate will continue to market the products through the existing distributor network utilizing both commercial and technical synergies.

Colin Gray, CEO of Pharmgate commented, “These important registrations give us the ability to further implement our forward integration strategy in providing quality products directly to the market. In optimizing our manufacturing to customer supply chain we control quality while bringing consistency, reliability and value to these markets. These acquisitions are further evidence of the successful Pharmgate/Jinhe franchise in the Americas.”

About Pharmgate LLC
Pharmgate LLC is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and other animal health compounds. The company has marketing or supply approvals for these products in most major markets throughout the world.